Abstract
In recent decades our understanding of immune cell activation and homeostasis has significantly expanded. Such progress helped to better define the cellular, molecular, and epigenetic networks involved in the immune response in the tumor microenvironment and renewed the enthusiasm towards the potential power of cancer immunotherapy. However, successful translation of novel mechanistic discoveries into effective immunotherapy was hindered by a number of obstacles, among them the ability of tumors to tolerize host lymphocytes rendering them functionally incompetent and the tumors ability to evade antigen-specific immune recognition through a variety of genetic, epigenetic, and stromal factors. These immunosuppressive strategies have, thus far, blunted our efforts to effectively unleash anti-cancer immunity. Fortunately, the wealth of new information regarding the interactions between tumors and the immune system and the regulation of certain highly antigenic tumor proteins has led to novel approaches with the potential to render cancer cells helpless towards immune attack. Here we summarize recent findings on cancer-induced T-lymphocyte tolerance and discuss a novel “vaccinate-induce” strategy conceived to counteract these effects at an epigenetic level.
Keywords: Histone deacetylase, tolerance, cancer testis antigen, cancer vaccine, DNA methylation, chromatin, immunotherapy
Current Pharmaceutical Design
Title: Circumventing Immune Tolerance Through Epigenetic Modification
Volume: 16 Issue: 3
Author(s): Jason A. Dubovsky, Alejandro Villagra, John J. Powers, Hong-Wei Wang, Javier Pinilla-Ibarz and Eduardo M. Sotomayor
Affiliation:
Keywords: Histone deacetylase, tolerance, cancer testis antigen, cancer vaccine, DNA methylation, chromatin, immunotherapy
Abstract: In recent decades our understanding of immune cell activation and homeostasis has significantly expanded. Such progress helped to better define the cellular, molecular, and epigenetic networks involved in the immune response in the tumor microenvironment and renewed the enthusiasm towards the potential power of cancer immunotherapy. However, successful translation of novel mechanistic discoveries into effective immunotherapy was hindered by a number of obstacles, among them the ability of tumors to tolerize host lymphocytes rendering them functionally incompetent and the tumors ability to evade antigen-specific immune recognition through a variety of genetic, epigenetic, and stromal factors. These immunosuppressive strategies have, thus far, blunted our efforts to effectively unleash anti-cancer immunity. Fortunately, the wealth of new information regarding the interactions between tumors and the immune system and the regulation of certain highly antigenic tumor proteins has led to novel approaches with the potential to render cancer cells helpless towards immune attack. Here we summarize recent findings on cancer-induced T-lymphocyte tolerance and discuss a novel “vaccinate-induce” strategy conceived to counteract these effects at an epigenetic level.
Export Options
About this article
Cite this article as:
Dubovsky A. Jason, Villagra Alejandro, Powers J. John, Wang Hong-Wei, Pinilla-Ibarz Javier and Sotomayor M. Eduardo, Circumventing Immune Tolerance Through Epigenetic Modification, Current Pharmaceutical Design 2010; 16 (3) . https://dx.doi.org/10.2174/138161210790170120
DOI https://dx.doi.org/10.2174/138161210790170120 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
New Generation of Oncolytic Herpes Virus
Current Cancer Therapy Reviews Mechanisms of Drug Resistance in Cancer Chemotherapy: Coordinated Role and Regulation of Efflux Transporters and Metabolizing Enzymes
Current Pharmaceutical Design Roles of EGFR, PI3K, AKT, and mTOR in Heavy Metal-Induced Cancer
Current Cancer Drug Targets Aberrant Splicing, Hyaluronan Synthases and Intracellular Hyaluronan as Drivers of Oncogenesis and Potential Drug Targets
Current Cancer Drug Targets Immunotherapy: A Potential Approach to Targeting Cancer Stem Cells
Current Cancer Drug Targets Tankyrases: Structure, Function and Therapeutic Implications in Cancer
Current Pharmaceutical Design Inhibitors of Chronically Active Ras: Potential for Treatment of Human Malignancies
Recent Patents on Anti-Cancer Drug Discovery Near-infrared Light Responsive Upconversion Nanoparticles for Imaging, Drug Delivery and Therapy of Cancers
Current Nanoscience The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets Regulation of P2X3 Receptor Structure and Function
CNS & Neurological Disorders - Drug Targets Dysregulated Post-Transcriptional Control of COX-2 Gene Expression in Cancer
Current Pharmaceutical Design Tumor Angiogenesis: A Target for Renal Cell Carcinoma Therapy. Current Perspectives and Novel Strategies
Recent Patents on Biomarkers Chemistry of Tumour Targeted T1 Based MRI Contrast Agents
Current Topics in Medicinal Chemistry In Situ Gels Based Drug Delivery Systems
Current Drug Therapy Diabetes and Complications: Cellular Signaling Pathways, Current Understanding and Targeted Therapies
Current Drug Targets Transductional and Transcriptional Targeting of Adenovirus for Clinical Applications
Current Gene Therapy Vitamins for Cancer Prevention and Treatment: An Insight
Current Molecular Medicine Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy Jab1-siRNA Induces Cell Growth Inhibition and Cell Cycle Arrest in Gall Bladder Cancer Cells via Targeting Jab1 Signalosome
Anti-Cancer Agents in Medicinal Chemistry Understanding the Interaction Between Human Serum Albumin and Anti-Bacterial/ Anti-Cancer Compounds
Current Pharmaceutical Design